Skip to main content
Top
Published in: Virology Journal 1/2012

Open Access 01-12-2012 | Research

Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides

Authors: Akimasa Fukui, Satoko Matsueda, Kouichiro Kawano, Naotake Tsuda, Nobukazu Komatsu, Shigeki Shichijo, Tetsuro Sasada, Satoshi Hattori, Kimio Ushijima, Kyogo Itoh, Toshiharu Kamura

Published in: Virology Journal | Issue 1/2012

Login to get access

Abstract

Background

Persistent infection of human papillomavirus (HPV) types 16 and 18 causes cervical cancer. To better understand immune responses to the prophylactic vaccine, HPV 16/18 L1 virus-like particles (HPV-VLPs), we investigated B cell epitopes of HPV16 L1-derived peptides.

Methods

Sera from mice immunized with HPV-16/18 L1 VLPs were analyzed for their IgG titers against 10 different HPV16 L1-derived peptides (20-mer) that contain human leukocyte antigen (HLA)-class I A-2, A-24 and class II DR.

Results

One 20-mer peptide at positions 300 to 319 was identified as a common B cell epitope in both Balb/c (H-2d) and C57BL/6 (H-2b) mice. Mapping analysis showed that the 10-amino-acid sequence at positions 304to 313 was an immunogenic portion. It is of note that the binding capability of this 10-mer peptide to the HLA-A2 and HLA-A24 molecules was confirmed by the HLA class I stabilization assay. In addition, one unique 20-mer was determined as a B cell epitope in each strain.

Conclusions

These results might provide new information for better understanding of immune responses to HPV 16 L1.
Appendix
Available only for authorised users
Literature
1.
go back to reference Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-527. 10.1056/NEJMoa021641.PubMedCrossRef Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-527. 10.1056/NEJMoa021641.PubMedCrossRef
2.
go back to reference Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005, 6: 271-278. 10.1016/S1470-2045(05)70101-7.PubMedCrossRef Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005, 6: 271-278. 10.1016/S1470-2045(05)70101-7.PubMedCrossRef
3.
go back to reference Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004, 364: 1757-1765. 10.1016/S0140-6736(04)17398-4.PubMedCrossRef Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004, 364: 1757-1765. 10.1016/S0140-6736(04)17398-4.PubMedCrossRef
4.
go back to reference De Carvalho N, Teixeria J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A: Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010, 28: 6247-6255. 10.1016/j.vaccine.2010.07.007.PubMedCrossRef De Carvalho N, Teixeria J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A: Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010, 28: 6247-6255. 10.1016/j.vaccine.2010.07.007.PubMedCrossRef
5.
go back to reference Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iverson OE, Hernandez-Ailta M: HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008, 26: 6844-6851. 10.1016/j.vaccine.2008.09.073.PubMedCrossRef Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iverson OE, Hernandez-Ailta M: HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008, 26: 6844-6851. 10.1016/j.vaccine.2008.09.073.PubMedCrossRef
6.
go back to reference Ryding J, Dahlberg L, Wallen-Ohman M, Dilner J: Deletion of a major epitope of human papillomavirus tyle16 virus-like particles. J Gen Virol. 2007, 88: 792-802. 10.1099/vir.0.82449-0.PubMedCrossRef Ryding J, Dahlberg L, Wallen-Ohman M, Dilner J: Deletion of a major epitope of human papillomavirus tyle16 virus-like particles. J Gen Virol. 2007, 88: 792-802. 10.1099/vir.0.82449-0.PubMedCrossRef
7.
go back to reference Tacchini-Cottier F, Weinkopff T, Launois P: Does T Helper Differentiation Correlate with Resistance or Susceptibility to Infection with L. major? Some Insights From the Murine Model. Front Immunol. 2012, 3: 32-PubMedPubMedCentralCrossRef Tacchini-Cottier F, Weinkopff T, Launois P: Does T Helper Differentiation Correlate with Resistance or Susceptibility to Infection with L. major? Some Insights From the Murine Model. Front Immunol. 2012, 3: 32-PubMedPubMedCentralCrossRef
8.
go back to reference Rammensee GH, Fried T, Stevanovic S: MHC ligands and peptide motifs: first listing. Immnogenetics. 1995, 41: 178-228. 10.1007/BF00172063.CrossRef Rammensee GH, Fried T, Stevanovic S: MHC ligands and peptide motifs: first listing. Immnogenetics. 1995, 41: 178-228. 10.1007/BF00172063.CrossRef
9.
go back to reference Guang Lan Z, Khan AM, Srinivasan KN, August JT, Brusic V: MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Res. 2005, 33: 172-179. Guang Lan Z, Khan AM, Srinivasan KN, August JT, Brusic V: MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Res. 2005, 33: 172-179.
10.
go back to reference Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res. 2004, 10 (3): 929-937. 10.1158/1078-0432.CCR-1117-3.PubMedCrossRef Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res. 2004, 10 (3): 929-937. 10.1158/1078-0432.CCR-1117-3.PubMedCrossRef
11.
go back to reference Imanishi T, Akazawa T, Kimura A: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. HLA 1991. Edited by: Tsuji K, Aizawa M, Sasazuki T. 1992, Oxford Scientific Publications, Oxford, 1065-1220. Imanishi T, Akazawa T, Kimura A: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. HLA 1991. Edited by: Tsuji K, Aizawa M, Sasazuki T. 1992, Oxford Scientific Publications, Oxford, 1065-1220.
12.
go back to reference Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N: AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009, 183 (10): 6186-6197. 10.4049/jimmunol.0901474.PubMedCrossRef Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N: AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009, 183 (10): 6186-6197. 10.4049/jimmunol.0901474.PubMedCrossRef
13.
go back to reference Komatsu N, Shichijo S, Nakagawa M, Itoh K: New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest. 2004, 64: 535-546. 10.1080/00365510410007008.PubMedCrossRef Komatsu N, Shichijo S, Nakagawa M, Itoh K: New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest. 2004, 64: 535-546. 10.1080/00365510410007008.PubMedCrossRef
14.
go back to reference Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K: Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol. 2000, 164 (5): 2565-2574.PubMedCrossRef Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K: Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol. 2000, 164 (5): 2565-2574.PubMedCrossRef
Metadata
Title
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
Authors
Akimasa Fukui
Satoko Matsueda
Kouichiro Kawano
Naotake Tsuda
Nobukazu Komatsu
Shigeki Shichijo
Tetsuro Sasada
Satoshi Hattori
Kimio Ushijima
Kyogo Itoh
Toshiharu Kamura
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2012
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-9-199

Other articles of this Issue 1/2012

Virology Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.